Fesoterodine for the treatment of urinary incontinence and overactive bladder (Q37429813)

20 August 2017

1 reference

title

Fesoterodine for the treatment of urinary incontinence and overactive bladder (English)

1 reference

20 August 2017

Pamela Ellsworth

1

1 reference

20 August 2017

18 November 2009

1 reference

Therapeutics and Clinical Risk Management

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

869-876

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

20 August 2017

start time

1 November 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

On the origins of the sensory output from the bladder: the concept of afferent noise

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Impact of fesoterodine on quality of life: pooled data from two randomized trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Human carboxylesterase isozymes: catalytic properties and rational drug design

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

The urothelium in overactive bladder: passive bystander or active participant?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Antimuscarinics for treatment of overactive bladder

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Prevalence and burden of overactive bladder in the United States

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Comorbidities associated with overactive bladder

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Urinary incontinence and depression

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

The total economic burden of overactive bladder in the United States: a disease-specific approach.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Influence of food on the pharmacokinetic profile of fesoterodine.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Pharmacokinetic profile of fesoterodine

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Comparison of fesoterodine and tolterodine in patients with overactive bladder

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Fesoterodine dose response in subjects with overactive bladder syndrome

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Costs of urinary incontinence and overactive bladder in the United States: a comparative study.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Estimated economic costs of overactive bladder in the United States

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

Determination of drug interactions occurring with the metabolic pathways of irinotecan

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2781061

A new questionnaire to assess the quality of life of urinary incontinent women

2 September 2018

1 reference

12 December 2020

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

12 December 2020

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

1 reference

12 December 2020

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder

1 reference

12 December 2020

Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study

1 reference

12 December 2020

Pathophysiology of overactive bladder and urge urinary incontinence

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity

1 reference

12 December 2020

Efficacy and tolerability of fesoterodine in women with overactive bladder

1 reference

12 December 2020

The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey

1 reference

12 December 2020

Identifiers

DOI

10.2147/TCRM.S6483

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

PMCID

2781061